UBS Group Cuts GoodRx (NASDAQ:GDRX) Price Target to $8.50

GoodRx (NASDAQ:GDRX) had its price target decreased by UBS Group from $9.00 to $8.50 in a research report report published on Friday morning, Benzinga reports. UBS Group currently has a neutral rating on the stock.

A number of other research firms have also recently issued reports on GDRX. TD Cowen upped their price target on shares of GoodRx from $14.00 to $16.00 and gave the company a buy rating in a report on Thursday, May 16th. Morgan Stanley lifted their price target on GoodRx from $7.00 to $9.50 and gave the stock an equal weight rating in a research report on Monday, June 10th. Royal Bank of Canada upgraded shares of GoodRx from a sector perform rating to an outperform rating and raised their price objective for the stock from $8.00 to $10.00 in a research note on Thursday, May 23rd. Barclays increased their price target on shares of GoodRx from $9.00 to $10.00 and gave the company an overweight rating in a report on Monday, May 20th. Finally, Raymond James upgraded shares of GoodRx from an outperform rating to a strong-buy rating and set a $10.00 target price for the company in a research note on Friday. One equities research analyst has rated the stock with a sell rating, four have given a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of Moderate Buy and an average target price of $9.36.

GoodRx Stock Down 6.0 %

Shares of NASDAQ:GDRX opened at $6.78 on Friday. GoodRx has a 52 week low of $4.14 and a 52 week high of $9.26. The company has a debt-to-equity ratio of 1.02, a quick ratio of 6.29 and a current ratio of 6.29. The company has a market cap of $2.54 billion, a PE ratio of -678.00, a price-to-earnings-growth ratio of 4.08 and a beta of 1.39. The firm has a 50 day simple moving average of $8.25 and a 200 day simple moving average of $7.39.

GoodRx (NASDAQ:GDRX) last issued its earnings results on Thursday, August 8th. The company reported $0.08 EPS for the quarter, missing the consensus estimate of $0.09 by ($0.01). The business had revenue of $200.60 million during the quarter, compared to analyst estimates of $200.47 million. GoodRx had a positive return on equity of 3.45% and a negative net margin of 0.86%. The business’s quarterly revenue was up 5.7% on a year-over-year basis. During the same period last year, the business earned $0.02 EPS. As a group, research analysts expect that GoodRx will post 0.17 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of GDRX. Rubric Capital Management LP bought a new stake in shares of GoodRx in the 4th quarter worth about $39,348,000. American Century Companies Inc. acquired a new position in GoodRx in the second quarter valued at about $18,183,000. Rip Road Capital Partners LP grew its stake in GoodRx by 25.8% during the fourth quarter. Rip Road Capital Partners LP now owns 1,763,277 shares of the company’s stock worth $11,814,000 after buying an additional 361,294 shares during the last quarter. Picton Mahoney Asset Management increased its holdings in shares of GoodRx by 24.3% during the second quarter. Picton Mahoney Asset Management now owns 607,090 shares of the company’s stock worth $4,736,000 after buying an additional 118,703 shares in the last quarter. Finally, GSA Capital Partners LLP bought a new position in shares of GoodRx in the first quarter valued at approximately $1,638,000. 63.77% of the stock is currently owned by institutional investors and hedge funds.

GoodRx Company Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.